BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20200500)

  • 1. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease.
    Sekine T; Konno M; Sasaki S; Moritani S; Miura T; Wong WS; Nishio H; Nishiguchi T; Ohuchi MY; Tsuchiya S; Matsuyama T; Kanegane H; Ida K; Miura K; Harita Y; Hattori M; Horita S; Igarashi T; Saito H; Kunishima S
    Kidney Int; 2010 Jul; 78(2):207-14. PubMed ID: 20200500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal manifestations of patients with MYH9-related disorders.
    Han KH; Lee H; Kang HG; Moon KC; Lee JH; Park YS; Ha IS; Ahn HS; Choi Y; Cheong HI
    Pediatr Nephrol; 2011 Apr; 26(4):549-55. PubMed ID: 21210153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
    Kunishima S
    Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness.
    Seri M; Pecci A; Di Bari F; Cusano R; Savino M; Panza E; Nigro A; Noris P; Gangarossa S; Rocca B; Gresele P; Bizzaro N; Malatesta P; Koivisto PA; Longo I; Musso R; Pecoraro C; Iolascon A; Magrini U; Rodriguez Soriano J; Renieri A; Ghiggeri GM; Ravazzolo R; Balduini CL; Savoia A
    Medicine (Baltimore); 2003 May; 82(3):203-15. PubMed ID: 12792306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome).
    Ghiggeri GM; Caridi G; Magrini U; Sessa A; Savoia A; Seri M; Pecci A; Romagnoli R; Gangarossa S; Noris P; Sartore S; Necchi V; Ravazzolo R; Balduini CL
    Am J Kidney Dis; 2003 Jan; 41(1):95-104. PubMed ID: 12500226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
    Sun XH; Wang ZY; Yang HY; Cao LJ; Su J; Yu ZQ; Bai X; Ruan CG
    Acta Haematol; 2013; 129(2):106-13. PubMed ID: 23207509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis.
    Miura K; Kurihara H; Horita S; Chikamoto H; Hattori M; Harita Y; Tsurumi H; Kajiho Y; Sawada Y; Sasaki S; Igarashi T; Kunishima S; Sekine T
    Nephrol Dial Transplant; 2013 Dec; 28(12):2993-3003. PubMed ID: 24042022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report of a young girl with MYH9 mutation and review of the literature.
    Landi D; Lockhart E; Miller SE; Datto M; Rehder C; Kanaly A; Thornburg CD
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):538-40. PubMed ID: 23007341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.
    Kunishima S; Yoshinari M; Nishio H; Ida K; Miura T; Matsushita T; Hamaguchi M; Saito H
    Eur J Haematol; 2007 Mar; 78(3):220-6. PubMed ID: 17241369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A; Panza E; Pujol-Moix N; Klersy C; Di Bari F; Bozzi V; Gresele P; Lethagen S; Fabris F; Dufour C; Granata A; Doubek M; Pecoraro C; Koivisto PA; Heller PG; Iolascon A; Alvisi P; Schwabe D; De Candia E; Rocca B; Russo U; Ramenghi U; Noris P; Seri M; Balduini CL; Savoia A
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes.
    D'Apolito M; Guarnieri V; Boncristiano M; Zelante L; Savoia A
    Gene; 2002 Mar; 286(2):215-22. PubMed ID: 11943476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [May-Hegglin anomaly: past and present--novel diagnostic test and new concept of the disease].
    Kunishima S
    Rinsho Byori; 2009 Jan; 57(1):54-9. PubMed ID: 19227191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.
    Arrondel C; Vodovar N; Knebelmann B; Grünfeld JP; Gubler MC; Antignac C; Heidet L
    J Am Soc Nephrol; 2002 Jan; 13(1):65-74. PubMed ID: 11752022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestation and molecular genetic characterization of MYH9 disorders.
    Provaznikova D; Geierova V; Kumstyrova T; Kotlin R; Mikulenkova D; Zurkova K; Matoska V; Hrachovinova I; Rittich S
    Platelets; 2009 Aug; 20(5):289-96. PubMed ID: 19557653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome).
    Selleng K; Lubenow LE; Greinacher A; Warkentin TE
    Eur J Haematol; 2007 Sep; 79(3):263-8. PubMed ID: 17655694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions.
    Kunishima S; Matsushita T; Kojima T; Amemiya N; Choi YM; Hosaka N; Inoue M; Jung Y; Mamiya S; Matsumoto K; Miyajima Y; Zhang G; Ruan C; Saito K; Song KS; Yoon HJ; Kamiya T; Saito H
    J Hum Genet; 2001; 46(12):722-9. PubMed ID: 11776386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old May-Hegglin, Sebastian, Fechtner and Epstein syndromes).
    Girolami A; Vettore S; Bonamigo E; Fabris F
    J Thromb Thrombolysis; 2011 Nov; 32(4):474-7. PubMed ID: 21842307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.
    Seri M; Cusano R; Gangarossa S; Caridi G; Bordo D; Lo Nigro C; Ghiggeri GM; Ravazzolo R; Savino M; Del Vecchio M; d'Apolito M; Iolascon A; Zelante LL; Savoia A; Balduini CL; Noris P; Magrini U; Belletti S; Heath KE; Babcock M; Glucksman MJ; Aliprandis E; Bizzaro N; Desnick RJ; Martignetti JA
    Nat Genet; 2000 Sep; 26(1):103-5. PubMed ID: 10973259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.